The Japan Pharmaceutical Manufacturers Association’s (JPMA) board issued on September 17 a reprimand to Pfizer Japan over its failure to report adverse drug reactions (ADRs). The company received a business improvement order from the Ministry of Health, Labor and Welfare…
To read the full story
Related Article
- Pfizer Japan Slapped with Biz Improvement Order over ADR Reporting
September 2, 2015
ORGANIZATION
- JPMA to Launch Nitrosamine Risk Project for APIs in FY2026
April 15, 2026
- Labor Group Chief Pushes Fundamental Drug Pricing Reform Ahead of Honebuto
April 8, 2026
- Drug Makers Step Up Self-Inspections for Supply Stability: FPMAJ Survey
April 8, 2026
- Pharma Labor Group Sees Wage Hikes in Low 4% Range as Talks Continue
April 7, 2026
- Generic Use Rate Hits 90% for First Time in October-December: JGA
April 7, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





